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Effector (TEM) and central memory (TCM) T cells have been
recently described as the main memory T-cell subsets
generated after primary immune response, with a potential
role in graft rejection after rechallenge with alloantigen.
Because of their effector function, they could be involved in
driving the response against the allograft, leading to
rejection. In this study, we sought to investigate the different
memory T-cell subpopulations in peripheral blood from a
cohort of 90 patients who underwent consecutive renal
transplant, and their association with acute rejection (AR)
episodes and induction therapy. Twenty-one of them were
monitored in the short term during the first 2 months
after transplantation. Three of them suffered an AR but
no changes in the circulating levels of either CD4þ or
CD8þ TEM were observed as compared with rejection-free
renal transplant patients. In total, 69 patients out of 90
were monitored in the long term. Even 2 years after
transplantation, maintained increased numbers of peripheral
blood CD4þ TEM were observed in patients suffering with AR.
Interestingly, induction therapy with thymoglobulin, but
not with basiliximab, produced an increase in circulating
CD4þ TEM cells at 6 months after transplantation. In
conclusion, our data suggest that AR episodes favor the
induction of TEM cells in the periphery of renal transplant
patients in the long term. It remains to be determined
whether such an effect has any impact on long-term renal
transplantation.
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T cells are under continuous education to be able to discern
between self- and foreign antigens. After leaving the thymus,
naı¨ve T cells can differentiate into many different subsets,
depending on the environment milieu in which they are
activated.1 Upon activation by professional antigen-present-
ing cells, naı¨ve T cells can differentiate into activated T cells,
driving primary responses against the antigen. After clearance
of the antigen, most of the T cells undergo apoptosis, whereas
the remaining T cells will be recruited into the memory T-cell
pool. Once the antigen re-enters into the host, those memory
immune T cells are able to mount a more efficient and faster
response against it.
In the transplantation setting, the memory cells can be
generated by several ways after previous encounters with
human leukocyte antigen molecules in sensitized patients
(after pregnancy, blood transfusions), and in non-sensitized
patients by cross-reactivity (molecular mimicry and bystan-
der proliferation),2,3 and homeostatic proliferation after
lymphopenia.4
In mice and humans, several populations of memory T
cells have been described with different effector functions,
tissue localizations, and phenotypic characteristics.5 The
central memory T cells (TCM) are confined to lymphoid
tissues, and express CD62L and CD45RO. They have a silent
phenotype and therefore could fit in a tolerance profile;
however, after reactivation, they could develop into effector
memory T cells (TEM), losing partially CD62L expression
with very strong effector properties and the capacity to drive
an effector response even without the requirement for co-
stimulatory molecules. There are different markers that help
to define these subpopulations: CD27, CD28, CD95, CD127,
and chemokine receptor-5 and chemokine receptor-7,
reviewed elsewhere.5
One important caveat is that most of the transplant
animal models that assess mechanisms of tolerance and
alloimmune responses are under pathogen-free conditions
in which the memory arm could be impaired or absent.
In spite of this argument, there are a number of models
in which the establishment of tolerance is not achieved
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in the presence of memory T cells,6 although treatments
blocking co-stimulatory pathways were able to prolong graft
survival.7
The involvement of memory T cells in alloimmune
responses is widely accepted and could have a role in the
development of a rejection episode and, more specifically, in
human renal transplantation. Nevertheless, such an issue has
been poorly investigated. The present study addressed the
changes in the number of circulating TCM and TEM in renal
transplant recipients undergoing an acute rejection (AR)
episode, as well as the effect that different immunosuppres-
sant drugs have on them.
RESULTS AND DISCUSSION
CD4þ TEM cells and their association with acute rejection
Within the increasing number of potential subsets involved in
the development of allograft rejection, the role of memory
T cells in AR pathogenesis was demonstrated as early as in the
70s in murine models.8 These cells are able to drive an AR
episode earlier and faster than naı¨ve T cells.9
After 20 years, two new subsets of memory T cells with
different properties were described (TCM and TEM).
10
Although both populations of CD8þ TEM and TCM were
able to mount an effective alloimmune response against the
graft in a skin graft model, the CD8þ TEM rejected allografts
better than TCM in the absence of secondary lymphoid
tissues,11 pointing to the TEM subset as a main candidate to
drive secondary alloresponses.
In human heart and renal transplantation, the degree of
AR was correlated with the degree of memory CD8þ T-cell
infiltration.12,13 However, in liver transplantation, an in-
creased infiltration of naı¨ve T cells was found.14 Further
evidence of the role of memory T-cell activation in AR was
demonstrated by the correlation of interferon-g production
measured by enzyme-linked immunosorbent spot with AR
and poor graft outcome.15,16
During the last decades, several groups have investigated
AR biomarkers, although because of good short-term results
with the use of new therapeutic strategies, the interest in
those biomarkers decreased. Despite this, 5–10% of kidney
transplant recipients still suffer from an AR episode. Within
the candidate biomarkers, memory T subsets have gained
interest within the transplant research community. In liver
transplantation, a recent study showed a shift from naı¨ve
CD8þ cells to the different memory subsets before AR
episodes.17 In human heart transplantation, an increase in
naı¨ve and a decrease in TCM CD4
þ cells before heart
transplantation in patients developing AR has been demon-
strated.18 Our group has studied the different subsets of
memory T cells in 21 renal transplant patients during the first
2 months after transplantation. Three out of the 21 patients
developed an AR episode and showed a decrease in the
percentage of CD4þ TEM and CD8
þ TEM during the first 2
months after transplantation (Figure 1a), although not
significantly, probably because of the less number of patients.
We were able to measure the number of circulating T-cell
subsets in an independent group of eight patients with
deterioration of renal function at the time of biopsy because
of suspicion of AR. In such a moment, the frequencies of
peripheral blood CD4þ TEM cells were increased, with a
trend toward decrease, or remain at the same level at 1 month
after biopsy (Figure 1b). Circulating CD8þ TEM cells did not
change at biopsy and at 1 month later (not shown). These
findings point to a possible role of CD4þ TEM immediately
after transplantation as inducers of the immune response
responsible for the AR and as AR biomarkers.
Induction therapy with thymoglobulin, but not with
basiliximab, induces increased levels of circulating
CD4þ TEM cells
One of the major limitations to the long-term success of
transplantation is the need for immunosuppression during
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Figure 1 |Changes in the frequencies of circulating TEM cells in early post-transplantation. (a) Frequencies of CD4
þ TEM (left)
and CD8þ TEM (right) cells in peripheral blood of renal transplant patients during the first 2 months after transplantation. Patients were
grouped according to the development of acute rejection (A) or not (N). Each dot represents one patient and horizontal bars
represent the mean value in each group. No significant differences were observed. (b) Changes in the frequencies of peripheral blood
CD4þ TEM cells in a group of eight patients at the time of diagnosis of acute rejection by biopsy and 1 month after biopsy.
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lifetime, and its deleterious effect on the graft and the
recipient. Understanding the impact of different immuno-
suppressive regimens on memory T cells would be a very
valuable tool in order to direct the therapy against the
harmful subsets involved in transplantation. In an interesting
in vitro model, after sorting CD8þ TEM cells cocultured with
different immunosuppressant medications currently used in
clinic, only the calcineurin inhibitor treatment was able to
suppress their function, as compared with mammalian target
of rapamycin inhibitors, steroids, or mycophenolic acid.19
This in vitro finding may have important consequences
regarding immunosuppressant therapy in early post-trans-
plant stages, as the TEM subset may have a role in driving an
AR episode.
In transplant models, several studies have recently been
published using pre-sensitized animals in which the inhibi-
tion of the memory arm after co-stimulation blockade
induction with anti-CD134L (OX-40L), anti-CD122 (beta-
chain of interleukin-2 receptor), anti-CD154, and anti-LFA-1
was effective to prolong heart graft survival but unable to
achieve tolerance.7
With regard to induction therapy regimens, a fast recovery
of blood TEM cells was observed after thymoglobulin
treatment, whereas TCM levels were restored only after 3
months post-treatment.20 In renal transplant patients,
Campath-1H induction evokes a severe lymphopenia, in
which TCM cells are more resistant to depletion, and
progressive restoration of TEM is found with time. Even
one rejection episode was associated with a higher propor-
tion of circulating CD4þ TEM cells.
21 In our cohort
population, we observed an increased proportion of CD4þ
TEM cells at 6 months after transplantation in those patients
who received thymoglobulin induction, whereas no differ-
ences were observed in patients without induction or in those
on basiliximab treatment (Figure 2). No significant differ-
ences in CD8þ TEM cell frequencies were observed at
6 months after transplantation in patients undergoing
thymoglobulin (30.7±15.0) or basiliximab induction
(29.7±14), as compared with those patients who did not
received induction therapy (33.5±12.0). Such a finding
could be related to the phenomenon of homeostatic
proliferation after the lymphopenia induced by thymoglo-
bulin.4 However, basiliximab did not induce lymphopenia
after induction treatment.
Kinetics of peripheral blood memory T cells in the
long-term follow-up
Although memory T cells may be mainly involved in AR,
with new induction therapies and depleting treatments, these
populations could have an important role in long-term graft
loss. There is evidence showing infiltration of memory
populations in biopsies of renal transplant patients diagnosed
with chronic allograft nephropathy.22 This is indirectly in
agreement with previous data from our group showing
decreased number of TCM CD3
þ cells in patients with long-
term failed grafts and reintroduced in the waiting list.23 In
the present study, we observed that even several months
after diagnosis, those patients suffering with an AR episode
maintained increased percentages of CD4þ TEM and CD8
þ
TEM cells (Figure 3), although it did not affect graft survival.
This is in contrast with the apparent decrease of both
TEM subsets in the short-term follow-up of those patients
suffering AR (Figure 1a and b). Nevertheless, the possible
effect of memory T cells on long-term prognosis and chronic
rejection in renal transplantation still awaits investigation.
CONCLUDING REMARKS
Despite the well-accepted role of memory T cells as initiators
of the potent secondary immune response, they have not
been particularly addressed as clinical biomarkers in the
setting of renal transplantation. In the present study, we
evaluated the quantitative changes in the two main memory
T-cell subsets, TCM and TEM, in the peripheral blood of
renal transplant recipients. Our data point to a possible role
of CD4þ TEM immediately after transplantation as inducers
of the immune response that would finally activate the
effector CD8þ TEM responsible for AR. There is practically
no data regarding the association between memory T cells
and chronic rejection in human renal transplantation.
The different immunosuppresive regimens seem to have
no quantitative effect on memory T cells. However,
induction therapy with thymoglobulin, but not with
basiliximab, induced increased numbers of circulating
CD4þ TEM cells.
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Figure 2 | Frequencies of CD4þ TEM cells in peripheral blood of
long-term follow-up renal transplant recipients at 6 months
after transplantation according to the induction therapy
received. Significant increased frequencies were observed in the
thymoglobulin (TG)-treated patients as compared with
basiliximab (anti-CD25)-treated patients or those not receiving
induction therapy. Each dot represents one patient and horizontal
bars represent the mean value in each group. Empty dots
represent patients who did not receive induction therapy.
Filled dots represent patients who received induction therapy
with anti-CD25. Triangles represent patients who received
induction therapy with TG.
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PATIENTS AND METHODS
Patients
A cohort of 90 patients who underwent consecutive renal
transplant in the Hospital Universitario Marque´s de Valdecilla
from September 2007 was recruited, and informed consent
given for participation in this study. All the clinical data were
recorded at the Nephrology Department. The patients were
divided into two groups depending on the time of follow-up:
the first group consisted of 69 patients with long-term follow-
up (6 months, 1 and 2 years after transplantation), whereas the
second one consisted of 21 patients with a short-term follow-
up during 2 months. Within long-term follow-up group,
15 patients suffered an AR episode (21.7%), whereas within the
short-term follow-up group 14.3% had an AR episode.
Immunological, demographic, and clinical parameters are
summarized in Table 1. No significant differences in these
parameters between the non-AR and the AR group were
observed in any of the cohorts studied.
Phenotype analysis
Four-color flow cytometry analyses were performed on
peripheral whole blood collected in heparin anticoagulant
tubes, within 2 h after collection. The blood cells were stained
with the following monoclonal antibodies (BD Biosciences,
San Jose, CA): anti-CD62L-fluorescein isothiocyanate, anti-
CD45RO-phycoerythrin, anti-CD4-peridinin chlorophyll
protein, anti-CD8-peridinin chlorophyll protein, and anti-
CD3-allophycocyanine. TEM cells were defined by their
phenotype CD45ROþCD62Lþ , whereas the TCM cells were
defined by CD45ROþCD62 L.
Cells were incubated for 30min in the dark at room
temperature. Subsequently, the erythrocytes were lysed after
10-min incubation with FACS lysing solution (BD Biosciences)
and washed with phosphate-buffered saline. After centrifugation,
the cells were resuspended in 0.2ml of phosphate-buffered saline
before acquisition of 50 000 events in lymphocyte gate by
FACScalibur flow cytometer. All the data were analyzed using the
CellQuest Pro software (BD Biosciences).
Statistical analysis
The data from both long- and short-term groups were
nonparametrically distributed (Kolmogorov–Smirnov test).
Differences in the percentage of CD4þCD45ROþCD62 L
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Figure 3 |Changes in the frequencies of circulating TEM cells in late post-transplantation. Frequencies of CD4
þ TEM (left) and CD8
þ
TEM (right) cells in peripheral blood of renal transplant patients during the first 2 years after transplantation. Patients were grouped
according to the development of acute rejection (A) or not (N). Each dot represents one patient and horizontal bars represent the mean
value in each group. Data were collected at 6 months, 1 year, and 2 years after transplantation. P-value is indicated when statistically
significant difference was found. Triangles in the left figure represent those patients who did not suffer acute rejection (N) whereas empty
dots represent patients who developed acute rejection (A). In the right figure, filled dots represent patients who did not develop acute
rejection (N) whereas empty dots represent patients who developed acute rejection (A). ESRD, end-stage renal disease.
Table 1 | Demographic, immunological, and clinical data from
short-term and long-term follow-up renal transplant patients
Short-term
follow-up
Long-term
follow-up
N 21 69
Donor age (years, mean±s.d.) 58±17.3 50.4±15.7
Recipient age (years, mean±s.d.) 63.3±7.2 52.8±12
Time on dialysis (days, mean±s.d.) 287±271 25.9±18.6
Number of transplants (1/2/3) (21/0/0) (49/15/5)
Acute rejection (yes/no, %) 3/18 (14.3) 15/54 (21.7)
Banff classification
(BL/Ia/Ib/IIa/IIb/H)
2/0/0/1/0/0 3/5/1/3/1/2
Kidney disease (% of GN) 33 36
Mismatches (A/B/DR, mean) 1.1/1.0/1.0 0.91/1.27/1.0
Induction therapy
(no/thymoglobulin/basiliximab)
Not
determined
46/6/17
Serum creatinine (mg/dl,
mean±s.d.)a
2.27±0.67 6 months:
1.52±0.44
1 year: 1.47±0.38
2 years: 1.51±0.46
MDRD (ml/min per 1.73m2)a 37.1±25.6 6 months: 51±14.8
1 year: 52±12.5
2 years: 51.3±14.9
Abbreviations: BL, borderline; GN, glomerulonephritis; MDRD, modification of diet in
renal disease; s.d., standard deviation.
aData in the short-term follow-up group are at 2 months after transplantation. In the
long-term follow-up, data are indicated at (6 months, 1 year, 2 years).
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TEM cells between the group suffering an AR episode and those
who were rejection-free were analyzed by using the Mann–
Whitney U test. The clinical and demographical parameters
were analyzed using Student’s t-test and Mann–Whitney U test
as appropriate. P-values o0.05 were considered significant.
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